Koninklijke Philips N.V. (PHG) Q2 2024 Earnings Report, Transcript and Summary

Welcome to the Royal Philips Second Quarter and Semiannual 2024 Results Conference Call on Monday, July 29, 2024. During the call hosted by Mr. Roy Jakobs, CEO; and Mr. Abhijit Bhattacharya, CFO, all participants will be in a listen-only mode. [Operator Instructions] Please note that this call will be recorded and replay will be available on the Investor Relations website of Royal Philips. I'll now hand the conference over to Mr. Leandro Mazzoni, Head of Investor Relations. Please go ahead, sir.

Hi, everyone. Welcome to Philips' second quarter and half year 2024 results webcast. I'm here with our CEO, Roy Jakobs and our CFO, Abhijit Bhattacharya. The press release and investor deck were published on our Investor Relations website this morning. The replay and full transcript of this webcast will be made available on the website after the call as well. Before we start, I want to draw your attention to our Safe Harbor statement on screen. You will also find the statement in the presentation published on our Investor Relations website. Roy, over to you.

Good morning, everyone and welcome. Great to be with you today. I want to start with the key highlights of this morning's release. We delivered strong order intake growth this quarter. Within a challenging macroeconomic environment, we achieved strong margin improvement supported by our productivity program, solid operational cash flow and comparable sales growth in line with our plan. The improvements were across all business segments and a result of the ongoing actions to enhance execution, supported by our innovations. We continue to make progress and see the effects of the focus on our 3 priorities: enhancing patient safety and quality; strengthening our supply chain reliability; and establishing a simplified, more agile operating model. Supported by key innovation launches and our ongoing actions, we are confident in our plan and reiterate our outlook for the full year 2024. On to the key financial highlights. Comparable sales growth was 2% in the quarter, on the back of high single-digit growth last year. This was driven by 4% growth in Diagnosis & Treatment and 2% growth in both the Connected Care and Personal Health segments. The adjusted EBITDA margin was 11.1% in the quarter, a strong improvement of 100 basis points compared to Q2 2023. Free cash flow -- outflow was €64 million which included the payment in connection with the Respironics economic loss settlement in the U.S. We delivered a strong underlying operational cash flow improvement which Abhijit will unpack later. I'm encouraged by the 9% order intake increase in the quarter. I'm confident that our innovative portfolio is well positioned to help hospitals worldwide address their staffing shortages, enhance productivity and improve patient and staff experience as are our leading innovations for consumers to take care of themselves. We continue to expect positive order intake growth in the second half and in the full year 2024. In China, orders declined as the industry-wide anticorruption measures imposed by the government continue to impact order lead times by hospitals as their internal approval cycles have increased to ensure compliance. I actually just returned from China last week, where I met many of our customers and partners. And it is clear that this remains an attractive health care market. We do not expect that the anticorruption measures impact structural demand. Our order funnel is active in the country and we expect China to gradually contribute to order growth in the coming quarters, albeit from a low base. This will be supported by the recently announced government program for renewal of aged medical equipment. Let me now provide you with some of the customer and innovation milestones during the quarter. We continue to see strong customer pool for our solutions and signed several long-term agreements across the world in this quarter. For example, we signed multiyear partnerships for monitoring, image-guided therapy and helium-free MRI with several university hospitals in the Netherlands and Belgium. We also signed a multi -- a major multiyear partnership with Bon Secours Mercy Health, one of the largest health systems in the U.S., standardizing innovative patient monitoring solutions across its 49 hospitals to drive better patient outcomes and reduce burden on staff. We launched our next-generation AI-enabled cardiovascular ultrasound platform with new FDA-cleared AI tools integrated to advance cardiovascular imaging and increase automation and productivity of our customers. Demonstrating our innovation leadership in minimally invasive treatments, we announced the first implant of the Duo Venous Stent System following premarket approval from the FDA. In Personal Health, we unveiled a series of innovations in China, including the launch of the first medical-grade Philips Lumea 8000 Series IPL hair removal device with cooling technology. Looking ahead, we remain confident in our plan, acknowledging that uncertainties remain in a challenging macro environment. In 2024, we expect to deliver further performance improvement with 3% to 5% comparable sales growth building on a strong comparison base of last year, an adjusted EBITDA margin of 11% to 11.5% and a free cash flow of €0.9 billion to €1.1 billion. I will now hand it over to Abhijit to take us through the Q2 financials in more detail. After which, I will come back on our execution priorities.

Thanks, Roy. Good morning, everyone. Let me start with our performance highlights. Comparable sales grew 2% in the quarter with 1% growth in mature geographies. Comparable sales in growth geographies grew 3% despite a decline in China. In Diagnosis & Treatment, comparable sales increased by 4%, with growth across Image-Guided Therapy and Precision Diagnosis. It's important to note that this was compared to strong double-digit growth in Q2 2023. The adjusted EBITDA margin improved by 160 basis points year-on-year to 12.2%. The increase was mainly driven by improved sales, pricing and productivity measures. Connected Care comparable sales increased 2%, with double-digit growth in Enterprise Informatics and flat comparable sales growth in Monitoring on the back of strong double-digit growth in Q2 2023. We saw strong performance in sleep systems and patient interface in markets outside of the U.S. Connected Care adjusted EBITDA margin improved to -- improved by 130 basis points to 8.8%, driven by solid performance in Monitoring and a strong step-up in profitability in Sleep & Respiratory Care which is encouraging. Personal Health delivered a 2% comparable sales increase driven by 5% growth outside of China. Overall, consumer sentiment in the U.S. and international markets is solid, while consumer sentiment in China remains subdued. The adjusted EBITDA margin for the segment improved significantly to 16.9% this quarter, mainly due to operational improvements and productivity. Sales in segment Other was €70 million lower than in the second quarter of 2022 -- 2023 due to royalty revenue phasing as indicated in our Q1 call. This difference alone resulted in a negative impact of around 160 basis points on the growth of the group in the second quarter. We have been very disciplined in cost management and our productivity initiatives delivered savings of €195 million in the quarter, of which operating model savings were €57 million, procurement savings was €71 million and other productivity programs delivered €67 million. The adjusted EBITDA margin for the group increased by 100 basis points to 11.1% despite the lower royalty revenue in the quarter. Productivity and pricing actions which contributed 320 basis points, partly offset by wage and component price inflation of 200 basis points. Earlier in the quarter, we also concluded an agreement with insurers to pay €538 million to cover the Respironics recall-related product liability claims. This income was recognized in Q2 2024 and the remaining payment is expected this year. Free cash was an outflow of €64 million in the quarter as it included a payment of €415 million in connection with the Respironics economic loss settlement in the U.S. partly offset by the initial receipt from insurers of €150 million. Therefore, excluding these 2 effects, free cash flow in the quarter was around €200 million, driven by higher earnings and continued progress in working capital management. Our leverage ratio improved from 2.8x to 2.2x compared to Q2 2023 on a net debt-to-adjusted EBITDA basis. It's also important to note that both S&P and Moody's upgraded our rating outlook to stable. We now have stable outlook for our strong credit ratings across S&P, Moody's and Fitch. The effective rate for the first half of 2024 was negatively impacted by the derecognition of deferred tax assets on the Respironics litigation provision and carryforward losses in the U.S. As a result, the effective tax rate for the full year 2024 will be high. Normalizing for these effects, however, the effective tax rate is expected to be between 17% and 19% this year compared to our guidance of 24% to 26% for the period 2023 to 2025. Now let's move to the dynamics in order intake. As mentioned earlier, we continue to see inherent unevenness in order growth between quarters. In the second quarter, order intake grew by a strong 9% driven by improvements outside China, particularly in North America. This resulted in 3% order intake growth for the first half of the year and we continue to expect to deliver order intake growth in both the second half as well as the full year 2024 as mentioned by Roy. As a reminder, orders and order book account for 40% of our revenue. The remaining 60% comes mainly from recurring revenue streams such as services and consumables from the book-and-bill business and from Personal Health. As mentioned in our previous earnings calls, we anticipate sales growth to be back-end loaded in 2024 due to the higher comparison base in the first 3 quarters of the year, where we grew 9% in 2023. We expect sales growth in the third quarter to stay broadly in line with the first half of the year on the back of 11% growth in Q3 2023 which was driven by mid-teens growth in Diagnosis & Treatment. For the full year 2024, we expect all business segments to be within the 3% to 5% sales growth range provided by the group or provided for the group, with Connected Care expected to be closer to the upper end of the range and Diagnosis & Treatment and Personal Health expected to be closer to the lower end of the range. With that, I would like to hand it back to Roy.

Thanks, Abhijit. I would like to continue with the progress we have made on our execution priorities. On patient safety and quality, we again delivered a substantial improvement in CAPA closures in the quarter, driven by stronger processes, capabilities and governance around it. We continue to drive significant simplification of the way we work and further reduced the number of quality management systems. We are well on track to achieve our target of 65% reduction in 2024. And we continue to invest in quality improvements across the portfolio and are acting fast on postmarket survey and signals. With respect to the supply chain, we now have lead times back to normal across all modalities. We will continue leveraging and regionalizing our end-to-end supply chain to further strengthen first-time-right deliveries and service levels. In China, we have reached around 90% local-for-local supply chain. Finally, our new operating model with prime accountability in the businesses has been live for almost 18 months now, resulting in significant productivity improvements of €1.4 billion to date. We have already reduced close to 9,000 roles. And at the same time, we continue the culture journey to drive impact with care and attracted more than 700 talents with HealthTech background this year alone. As announced earlier this year, Abhijit will retire from Philips after a long and illustrious career with us. I want to thank him for his significant contribution to the company, especially during his time as CFO. Abhijit's leadership, passion and education have helped shape the transformation of Philips over the last decade and guided the company through global uncertainty in recent years. We will certainly miss Abhijit for his drive, counsel and his sense of humor. His last day will be on September 30. So you will have the opportunity to engage with him during the road show and investors events over the next couple of months. Our incoming CFO, Charlotte Hanneman, joined us last month and will move into the CFO role on October 1. Abhijit and Charlotte are working diligently to ensure a smooth and seamless transition. As you know, Charlotte brings over 20 years’ experience in med tech and pharmaceutical industries, most recently, at global medical technology company, Stryker. Before I wrap up, I want to take the opportunity to extend a warm invitation for our Show and Tell event for investors and analysts in September. It will be a great face-to-face event in the Netherlands. We will take you on to a deep dive into other businesses and highlight some of our most important products and innovations. You have the opportunity to directly discuss the latest trends in the HealthTech segments with our management and our business teams. Our Investor Relations website contains more information on the event and how to register. We look forward to see you here. Let me close out by repeating the key messages of today's announcement. We delivered strong orders and margin improvement, solid operational cash flow and comparable sales growth in line with our plan within a challenging macro environment. This was a result of progress on our execution and our industry-leading innovations. Supported by key innovation launches and our ongoing actions, we are confident in our plan and reiterate our outlook for the full year 2024. I would like to thank you for joining the call and we will now take your questions.

[Operator Instructions] Our first question comes from the line of Hassan Al-Wakeel from Barclays.

I have three, please. Firstly, on orders, can you talk about the strength you're seeing in North America and to what extent? Is it a catch-up on supply issues around MR or, indeed, share gains in other modalities as well? Secondly, can you talk about the Personal Health business in China which looks to be down around 10% in the quarter? What are your expectations here for the second half? And can you talk about the building blocks and the assumed acceleration in the broader PH business over the next two quarters? And then finally, you had an impressive margin delivery in the first half. And with the seasonally strong second half that you typically enjoy, coupled with Connected Care margins building from here, why haven't you raised guidance? Is this a continuation of the conservatism that we've seen from you, Roy? Or is there something we should be aware of, incrementally driving caution into the second half?

Thank you, Hassan, and great questions. Let me start with the first one, orders and the strength in North America. So actually, we have seen improvement of our order book across different businesses, building on the strength in the market first place because North America clearly is the strongest market in the world, where we have seen our customers strengthen their, actually, P&L, their income through more patients that are being served. But also, we see further consolidation trends in the market that actually we benefit from as they are choosing key partners that they trust in for longer-term technology partnerships. And actually, we have seen that across our portfolio, whether that's on monitoring, whether that's on imaging and interventional. And also, you have seen and heard us talk about a very strong Enterprise Informatics growth because you see that especially software and AI is used very much to improve productivity and also to reach across different sites, whether it's different hospital sites but also into ambulatory and sometimes even into home. So that, actually, portfolio that we have is resonating well with our North American customers. So that's also what we see in the order intake. So also, therefore, we don't expect that this is a one-off. We will expect actually the order intake to continue to be strong in North America. Then the second question on PH. China was indeed down. I think that was a market and industry kind of phenomena. Consumers are spending less in China than we were used to. We also expect that actually to continue in the second half. So whilst we expect some strengthening, we don't expect too much from China market. But what you have seen and also in terms of our guidance, we do see that actually the growth in other parts of the world is stronger and actually will also strengthen in the second half of the world. North America is part of that. We already saw stronger growth in Europe and some of the Asian markets already in the first half and that combination actually will also help us deliver the full year guidance as we have laid out. On the other hand, what you also saw in PH is that we are driving strongly the profitability. We have been taking strong action on further productivity initiatives but also some support from pricing. So the overall mix is playing out well and supporting PH to step up in profitability levels. Then the third question on the margin delivery in the first half. I think, yes, we are satisfied that we continue to see the margin improvements, of course, backed by a very strong productivity drive on one hand, the return to sales and also stronger underlying margins. So in that sense, we expect that momentum also to continue into the second half. At the same time, we didn't want to raise midyear. We feel that kind of -- it's better to stay kind of confident on the full year, deliver quarter-over-quarter our improvements and, by doing so, making sure we deliver the full year. So we stick to our plan, the 3 priorities that we have, building on the innovations that we can get out there and, by doing so, working towards that delivery for the full year.

Let me -- to add a bit. Hassan, if you look at the improvement in the first half, we are in the guided range of 40 to 90 bps. So therefore, there's no need, at this stage, like Roy said, to again further improve it because we are in the guided range of profit improvement also for the first half of the year.

The next question comes from Richard Felton from Goldman Sachs.

Two for me, please. So first of all, on some of the recently launched innovation, I think you've -- you mentioned new products across CT, IGT and Ultrasound or fairly recently. So in context of those launches, how do you see your current market share trends across those key modalities? That's question one. Then my second one is on Enterprise Informatics. Is there any color or detail you can share to help us think about profitability for that division as the business scales?

Thank you, Richard, for these questions. Good questions again. If you look at the NPIs and how they support market share, I think what you can see from the order intake growth, 9% in the second quarter, 3% first half, that actually supports a strong performance in the market. Some of these new innovations, we just recently launched, like, for example, the Ultrasound, a new platform with AI that's, I think, very exciting. Now we expect the benefits to come from that platform. That has not yet been kind of built into delivery to date, the same for some of the new launches of Azurion and the CT 5300 because we had the first launches of these. I think you will see -- and we also believe to see that back in our market share in the coming months and even in 2025 whilst we got this to full strength. So we have seen, of course, strengthening our positioning in the market. We also see very good resonance. We had multiple deals across the world. You saw not only in North America that we closed big technology partnerships but also in Europe, various ones and also in Asia. So actually, you see that we have gone up, I think, increased momentum based on our innovations. The other, I think, achievement that we highlighted which is important also for competitiveness, is that we're now fully back on track with supply chain lead times. So we had MR which was the last one to kind of really fall in line. We also have that now back. We also have seen that kind of reflected in MR momentum and we expect that to support also our way forward. And on the second question on EI, I think what we have seen indeed is that there's strong order intake that also, of course, drives then conversion. And we also have seen that contributing to profitability. And that's something that kind of we are happy with. So we saw that coming into positive contribution. And what we said for the long term, this €1.5 billion sales and moving towards double-digit margin is something we are driving full force towards, of course, step by step, quarter by quarter. But it's clear that, that portfolio is gaining momentum and that then also translates into improved contribution.

Our next question comes from the line of David Adlington from JPMorgan.

Maybe just a question around pricing. Of the 2% growth on sales, you saw this quarter, how much of that was down to price? And then following on from that, how do you see the pricing environment evolving? Are you seeing positive trends, flat pricing? Or we're seeing some pressure on pricing at this point?

Yes. I think if you look, we saw some pricing benefit in health systems and that's what we've been saying for the last couple of years, David, that we saw it in our order book and now we see it translating back into the P&L. In terms of PH, you don't really see further pricing upsides now because you see how the consumer sentiment is. It's quite subdued. So pushing pricing at this time is not helping now. Of course, we are working on the productivity as well as the operational improvements that we had put in, be it in supply chain, be it in our factories, etcetera and that you see contributing nicely back in the margin. So net-net, between PH and health systems, I think the net pricing impact was close to 0. But in health systems, we got a positive impact and less so in Personal Health.

And maybe just a follow-up there. On the orders that you're getting there, how is the pricing on the orders?

Yes. So far, still okay but we will have to see how it goes in the coming quarters and see the competitiveness. But so far, we are still holding and we are making good progress with our material price reduction. So that's helping, let's say, the profitability looking forward.

Our next question comes from the line of Veronika Dubajova from Citi.

I have 3, please, if I can. The first one is just a follow-up, Abhijit, on your comment that you're expecting D&T growth for the full year to trend at the lower end of the 3% to 5%. Can you maybe just elaborate what it is that's making you somewhat more cautious here about the second half -- in the second half of the year? I guess we're at 4% year-to-date. So I'm just curious what drives the slowdown in the back half of the year, especially given the easier comps? That's my first question. My second question is just a follow-up on your margin guidance for the year. I look at the first half of the year, you've delivered 90 basis points of improvement. The comps in the back half get easier. So I think Hassan asked the question about the conservatism in the guidance. But just to maybe reiterate that there is nothing specific that worries you about the margin development in the second half of the year, that there are no specific headwinds you want to flag as to why the margin improvement in the back half should be, at best, similar to first half or potentially worse. And then my final question is for you, Roy, on China, having just visited there this past week. It'd be great to get an update on how you feel the behavior on the ground is. And I guess as you think about your sales in China and your orders in China in the back half of the year, what are your expectations for each of those when it comes to return to growth and the timing of that?

Veronika, let me take the first couple of questions. I think if you look at the -- for Q3, we had really dramatic growth last year, I think, even in the mid-teens, that makes the comparable stuff for the third quarter which is why we expect to be at the lower end of the guidance. Now we will see also how China plays out and the speed at which the orders come in. So we will have to match both of those. So for now, that's how we are looking at our forecast for the rest of the year. Yes, I think Roy answered the question on full year margin, right? We have 90 bps up. That's in line with our guidance. There's still a second half to go. We are not going to change guidance every quarter. So for now, we reiterate our confidence to be in the guided range, maybe in the upper end but we will not change guidance at this stage. The third question...

Yes, on China. So let me -- so indeed, it was good to be in China again because staying close to the bulls of the market is important. At this stage, I spoke to customers, partners and, of course, to our own team. Now I think what you do see is that, on the one hand, there is still impact that is flowing through from the measures that have been taken. I think we are not yet out of the woods but we do see improvement coming into the activities. And that's also something that I saw and discussed with customers. I saw the activity of the order funnel. I saw it also in discussion with our own teams. That's also what we expect to showcase in due course of the second half. Then, of course, normally orders go ahead of sales. So that's a logic you would also expect in this recovery pattern. The exact timing is hard to gauge because yes, we have seen it all in the last months and even over a year, that is not exact to pinpoint what is there and how it will evolve. But we said early this year that kind of second half will be better than the first half. We still expect that. We also have seen sequential improvement in Q2 and we actually expect that to accelerate into the second half. So I think that is what I have to say to China. And then next to the fact that, fundamentally, this is a very strong market and holds, of course, a lot of patients to be taken care of for the future as well. We have been adjusting our local-for-local footprint innovations so that when the demand comes, we are ready to capture it and then kind of it's waiting about the exact development of it.

And can I just follow up? Any thoughts at this stage that you have about the stimulus and how meaningful that could be? I appreciate you don't have a sense of timing yet but just conceptually, as you look at China over the next 1, 2, 3 years, do you think the stimulus could be meaningful in terms of driving order and sales growth in China or not?

No, I've said before, how I look at it, I see it as a kind of bonus program that the China government has put in place. I think the China market has fundamental underlying growth that we should count on and then this will be on top of. So that this will accelerate to a certain extent, for sure, right, because there's extra money that will flow into the market that actually probably will kind of speed up some of the replacements in the market to go faster than they would normally do. And we also expect that, that will contribute and we will benefit from it. But, a, the China government did not give specific amounts that they ultimately will release. B, we don't know exact timing. And therefore, it's kind of, I would say, too early to kind of really put numbers on top of it that kind of will come forward. And for me, this is part of the overall recovery and improvement trajectory that will come, where I expect more of just underlying structural demand kind of to drive the improvement and the stimulus but the stimulus will be a part of it.

Our next question comes from the line of Hugo Solvet from BNP Paribas Exane.

Congrats on the print. I have 3, please. First, a clarification on China, Roy, if you can. Do you see a risk that customers' order acceleration or the recovery be hold off in H2 as they will be waiting for the stimulus? Second, on Connected Care and -- Sleep & Respiratory Care, sorry, can you quantify for us the margin step-up in that business year-on-year? But also, are you seeing a sequential margin improvement given, I think, that you are already breakeven in Q1? And lastly, on PH. So obviously, D&T strong. Connected Care is gaining momentum. The settlement is now behind. Just want to get a feel of your level of commitment to the Personal Health business.

All right. Thank you, Hugo. Also great questions. Let me start with the first one on China. So I don't actually expect that the China customers will hold back on placing orders because they're waiting for stimulus. As I said, there are 2 parts of demand. The most important is the underlying kind of demand for replacement of the installed base or even for new investment. There's also some pent-up demand from the period that kind of the order lead times were under pressure. So I expect that will drive the improvement itself. Then stimulus, they will have to wait until that becomes clear. So that is the waiting but that's more on top of -- that's also where I said kind of it's hard to gauge when that exactly will come to market but I don't think this will hold off the full improvement of China in the second half that we project. Then on Connected Care, indeed, we are happy to see SRC regaining momentum, started, of course, with the sales momentum outside of the U.S. then also, of course, for the remaining part of the business that we have in the U.S. We also see actually good momentum and we have been rightsizing the business based on the clarity that we got. So we took also then the productivity measures. Now that brought Sleep & Respiratory Care back into the positive. We already mentioned that in the first quarter and we actually see that contribution strengthening. Now I'm going to call out exactly how that looks like because we don't do that for any business. But I can confirm that we have seen further strengthening of the profitability profile also in the second quarter. And that's actually what we will continue to build on in the third and fourth quarter as also some of these further measures that we have been taking will come into effect. And then on the third one, on PH. I think we are very excited about our PH portfolio. As we mentioned before, we have some exciting innovation launches that are coming out. You saw the strong profitability step-up. So this business is also still very attractive from a profile of cash contribution and profitability contribution. We are also the good owner because we have market-leading positions. We are number 1 and 2 in all the segments that we play, whether it's in oral care, whether it's in personal care, whether it's in MCC. And we see also, over time, that care will move more to the home. So actually having a strategic position in the home, being active there ourselves, does also give us currently already a differentiating position in the health care market because customers that are looking, hospital systems that are looking how to better serve in an ambulatory setting or in a home setting also value our insights, also value our brand even in terms of what it does in the home. So full commitment, I'm excited about that part of the portfolio as much as about the rest and also seeing kind of a good future for it.

Our question comes from the line of Julien Ouaddour from Bank of America.

The first one in D&T. So in your prepared remarks, you mentioned growth in IGT and Precision Diagnosis. But I mean what about Ultrasound this quarter? And I think we've seen data from China which suggest that you -- I mean you lost important market share in Ultrasound for the country during the first 6 months of the year. So any particular reason for that? The second question on, let's say, like on Respironics. So we've also seen some like European class action for Respironics emerging this summer. Could you maybe just update us on the situation and like let us know what the potential outcomes are in your view, any, let's say, increase in terms of provisions like for the litigation going?

Julien, let me clarify on Ultrasound. We had tremendous growth last year in the first half of the year. It was above 30% growth. So based on that, basically, we are -- we don't have growth in the first half of this year because we were getting out of the whole supply chain situation. So if your question was on Ultrasound, I think that tells you I -- so therefore, I don't know where you have this information on market share loss but I think Roy also has told you about our new product launches which we are excited about. So we expect to continue to strengthen in that area. Your second question...

Let me take that one. That's, I think, on the SRC. So indeed, last time, we're very happy to kind of announce that we got the North American settlement with finality. We also mentioned at that time that there are cases ongoing outside of United States. You saw the European class action recently kind of announced. Actually, we have, so far, very limited information, have not been served with a complaint. We expect it will be in the same vein as what was kind of put forward in the U.S. There's nothing currently that we can say about it. And the extent that we will defend ourselves in this, we will build on the testing that we have also used in the North America case and therefore, we will address it in a rigorous manner with the best team on it. But there's nothing currently to be said about it. That's also why you have not seen any kind of implications of it. It's very early days. And it's one of the cases that we will take forward as part of dealing with the cases outside of the U.S. Maybe last comment, of course, is in a very different legal system than in the U.S. So also in terms of even if then actually consequence would be of different scale than to be expected in the non-American case. But as I said, it's even too early to go there because we don't even know if there's anything of meaning.

Perfect. Perfect. And a very quick follow-up in order intake. Could you maybe give us a bit more color about the breakdown by modality for this quarter?

No, actually, that's -- Julien, we would love to and we used to but our competitors don't and therefore, for us to now give that makes it a bit too sensitive for us to give. But overall, I think Roy mentioned that outside of China, we have done well, with particular strength in North America.

Our next question comes from the line of Robert Davies from Morgan Stanley.

I had a couple. One was just on the competitive environment in D&T, whether you're seeing any changes there. You mentioned, I think, in your earlier comments about progress in North America. I know you didn't want to sort of call out specific modalities but just if you could give us a little bit more color in terms of areas of relative strength and weakness in the quarter where you're making particular progress with clients, that would be helpful. And then the other one was just around the free cash flow guide given where we are year-to-date. What sort of underpins your confidence in getting into that €900 million to €1.1 billion range over the full year?

So thank you, Robert. Let me take the first one, competitive environment in D&T. I think what you have heard us say and actually, you also see it in some of the deals we closed is actually that you see and that's why we're excited about the contribution that actually all businesses are contributing in order kind of growth and also kind of how we position in the market. And you saw that also back, of course, then ultimately converted into sales. The North American market has particular dynamics in terms of certain strongholds that we hold in monitoring and in kind of IGT and Ultrasound. So that's known. So of course, they are based upon the strength that we have. We take, on average, more from the market. We are also kind of bouncing back in imaging based upon the lead times improvement that you have seen, the launches that we are doing. We also have been working on our team. So that's something that kind of we are also excited about on top of the Enterprise Informatics side is something that really resonates very well in the North American market and also supports our D&T portfolio because you see, of course, that PACS, that's on top of imaging, you see that digital pathology goes in the same vein. You see that kind of some of the solutions that we're now deploying in Ultrasound are very AI driven. So actually, that interplay between software, AI, informatics and then also the D&T portfolio is something that differentiates us in the market and, therefore, helps us to be productive in North America.

Yes. On the free cash flow, if you look up, we had this payout for the economic loss settlement which actually makes the numbers a bit skewed because the insurance money will come in the second half, the payment has happened in the first half. If you just normalize for that, our cash flow for the first half of this year is maybe €150 million behind last year. So it's not hugely behind. And last year, we delivered a cash flow of €1.6 billion. This year, we are planning €0.9 billion to €1.1 billion. And Q4 is a big cash flow quarter for us. So confidence is actually very high with the improved earnings and working capital management that we will get to our guidance on free cash flow.

Very clear. Maybe just one quick follow-up around Personal Health. I know you called out the weakness in China but maybe could you just provide a little more color on what you're seeing in the North American market in Personal Health?

Yes. I think North America, overall, we seem to be gaining share. Now the consumer confidence is not buoyant but it still remains solid as we have said. We have been gaining share. The sellout has been good given the current market situation. And then based on the product launches that we are planning in the second half of the year, we expect to have reasonable growth in North America as well.

Our next question comes from the line of Sezgi Ozener from HSBC.

I will have 3, please. First of all, on the legal front, do you have any update on the DOJ case? And on the rest of European cases and elsewhere, can you give a highlight of what we can -- we might be looking into in terms of time lines and sizes? And second question on the Connected Care segment. What does the portfolio look like post all the pruning on the respiratory care and ventilation segment? Do you expect to be present again on a considerable scale on ventilators and respiratory care? And the last one is on reimbursement front. Do you see any changes in your DME market and outlook? Do you see more inclusion in reimbursements in Connected Care that is affecting your margins? I mean we've heard from some peers that usually on this front, DME margins tend to be much stronger than -- compared to when products get included in the PBM payment scheme. So do you see any changing dynamics from that front?

Thank you, Sezgi. Let me start off with the first question on the legal cases. So on the DOJ, there's no further update. Otherwise, indeed, you would have heard. We have been further collaborating with the DOJ but there is no position on that to be shared, no news also from the investigation. It's ongoing and we work collaboratively with the DOJ on it. Similar for the rest of the EU cases. Actually, we are in the kind of the various cases in the dialogues that need to happen. But there's no insight in outcome nor in the need for kind of any provision or kind of even any preclusion on impact. So in that sense, there's no news on the front of litigation beyond what we have also disclosed in the half year report. So that's the first. And on the second, in Connected Care, yes, we have been pruning. Actually, you also see that the remaining part of the portfolio is working. We see the growth returning. We see profitability returning. Yes, as a result of pruning, there will be a less broad portfolio but we still are relevant. We have the core products that have been kind of the biggest volume drivers for us in respiratory care, both in sleep as well as respiratory and we keep active in both sides. So that's something that remains part of the plan. It's also what we get back from our customers that really like our innovations also kind of with the Care Orchestrator that combines both and so does both. So it's not only the devices but the software. And then the third one, reimbursement DME. To our knowledge, there's no specific change or strengthening of that. What we have seen is that actually the demand is out there. The patient gone up that are unaddressed out there, they're coming into it. They're also reimbursed and that's something that drives the respiratory and sleep market as it has been doing it before. So we have not seen any specific order changes in dynamics that we would like to report on. I think SRC is regaining momentum. And that's what we are seeing and that's what we are very excited about. And that's especially in terms of outside U.S. and sales and across the portfolio with profitability contribution.

And maybe as a quick follow-up. Post the pruning and post the ex-U.S. expansion in sleep care, where should we consider the contribution to Connected Care from Sleep & Respiratory Care? Is it closer to the 20% range we've seen in '23? Or is it closer to almost -- it used to be half of the Connected Care sales is probably a further target. But where should we see it?

Sezgi, I think what we've said before, this used to be a €2.3 billion business. We have resized it now to €1 billion business. So that's the size you should take. And then let's say, from there, from next year onwards, you will start seeing growth in the Connected Care guided range of 3% to 5%. I think that's how you should model it.

I see. So just under the 20% range, it seems. Okay.

Our next question comes from the line of Falko Friedrichs from Deutsche Bank.

My first question is on your good 9% order intake growth in Q2. Is there any reason that this growth number should be lower in Q3 and Q4 considering the improvements in North America and then also potentially in China? Maybe you could briefly remind us of the comps as well for the orders in the second half. And then my second question, I'm piecing together your comments on China stimulus. Did I sort of understand it correct that you should start to see a positive impact in orders in the second half and then a positive impact in sales, probably not before 2025?

Yes. Let me take the first one on order intake. So as I mentioned also in my opening remarks, like don't extrapolate the 9% because order intake has been extremely lumpy. Therefore, we are at the 3% for the first half year. We expect to have growth in the second half. We don't know the exact amount because it also depends on how the whole recovery in China happens. But -- so I think that's how you should look and not extrapolate the 9%. Comps of last year were also similarly negative for the second half and the first half. So that will not make a big difference. I think the strength in North America will continue. The strength in international markets will continue and then the only unknown piece in the puzzle is how China recovers. That's how you should look at the order intake for the second half. The next question was, yes, again, very difficult to say whether it will contribute a bit but it's not likely to be major in the second half. So yes, the bigger contribution will be in 2025. The speed at which we get the orders will depend how much contributes to this year but that's something we still have to watch in the coming months.

The last question comes from the line of Ed Ridley-Day from Redburn.

Just a follow-up firstly on Ultrasound. Thank you for your earlier comments but can you give us a little bit more color about the growth ex-China in that business? That would be helpful. And also in Image-Guided Therapy, coming through a double-digit growth in that business from -- in terms of the revenue growth for IGT or if you can provide any further color on that business as well, I'd be grateful.

Yes, I need to check my numbers on the Ultrasound growth excluding China. But again, like I mentioned, for the first half of last year, we had a 30% plus growth. So I don't expect us to have any significant growth outside of China. It will also be a decline outside China because last year, we were getting past the whole supply chain issue. So actually, we had massive supplies in the first half of last year. Regarding IGT, we are seeing a slow recovery. This quarter was good but I don't see -- this year has been in the double-digit territory. It will probably be lower than that. But that's included, let's say, in our overall guidance for D&T.

Gentlemen, that was the last question. Please continue.

Yes. Maybe first of all, let me thank everybody for joining the call since this is going to be my last analyst call and last quarter after 50 quarters of doing this both as IR and as the CFO. Just wanted to say a big thank you to all of you for putting up with me in a way and we've had some difficult times but a lot of very good times and I look forward to that. We look forward to seeing you on the road show later this week for those who I will meet and later in the year in our Show and Tell event. But since there will be a lot on this call, who I will not probably meet in my current capacity, a big thank you. And again, thank you for joining the call.

Thank you, Abhijit. And indeed, thanks for all the contribution, as I said before, memorable times. So I'm happy to see you also kind of transitioning well. Let me close out this call by repeating, I think, the key message of today. Firstly, we delivered strong orders and margin improvement, a solid operational cash flow and comparable sales growth in line with our plan and that within a challenging macroeconomic environment. This was the result of progress on our execution and our industry-leading innovations which we keep focusing on. And supported by our key innovation launches and our ongoing actions, we're, therefore, confident in our plan and also reiterate the outlook for the full year 2024. I would like you -- to thank you for joining the call and I wish you a great summer. Thank you so much.

This concludes the Royal Philips second quarter and semiannual 2024 results conference call on Monday, July 29, 2024. Thank you for participating. You may now disconnect.